Posted On: 10/09/2014 9:07:27 PM
Post# of 30066
We are in the Fourth Quarter so, Could begin at any time, tick tock. This will be an interesting game of musical chairs.... And this is only for LymPro....
Amarantus anticipates launching LymPro in the fourth quarter of 2014 .
Amarantus plans to launch LymPro for RUO in the fourth quarter of 2014 , primarily targeting pharmaceutical clinical trials.
Amarantus anticipates completing enrollment of the 68 patient LP-002 extension in the fourth quarter and will announce data from an in-depth analysis from the full cohort of 140 subjects (72 patients + 68 patient extension) shortly thereafter .
full steam ahead
now tailor our initial marketing efforts towards the $150M RUO market , primarily targeting pharmaceutical companies engaged in Alzheimer's disease therapeutic trials.
We have nearly completed assembling the resources needed to launch LymPro to the RUO community in the fourth quarter
Thereafter , we intend to market LymPro to the broader medical community, initially under CLIA. We estimate the worldwide market for an Alzheimer's diagnostic is $3B
The company will make a final decision on which version of LymPro (Version 1 or Version 2) to launch under the CLIA designation, which will be marketed to the general population, following an in-depth analysis from the full cohort of 140 subjects.
The company anticipates launching LymPro under CLIA shortly after product launch in the RUO marketplace.
http://ir.stockpr.com/amarantus/company-news/...mpro-testr
Amarantus anticipates launching LymPro in the fourth quarter of 2014 .
Amarantus plans to launch LymPro for RUO in the fourth quarter of 2014 , primarily targeting pharmaceutical clinical trials.
Amarantus anticipates completing enrollment of the 68 patient LP-002 extension in the fourth quarter and will announce data from an in-depth analysis from the full cohort of 140 subjects (72 patients + 68 patient extension) shortly thereafter .
full steam ahead
now tailor our initial marketing efforts towards the $150M RUO market , primarily targeting pharmaceutical companies engaged in Alzheimer's disease therapeutic trials.
We have nearly completed assembling the resources needed to launch LymPro to the RUO community in the fourth quarter
Thereafter , we intend to market LymPro to the broader medical community, initially under CLIA. We estimate the worldwide market for an Alzheimer's diagnostic is $3B
The company will make a final decision on which version of LymPro (Version 1 or Version 2) to launch under the CLIA designation, which will be marketed to the general population, following an in-depth analysis from the full cohort of 140 subjects.
The company anticipates launching LymPro under CLIA shortly after product launch in the RUO marketplace.
http://ir.stockpr.com/amarantus/company-news/...mpro-testr
(0)
(0)
